Anzeige
Mehr »
Mittwoch, 29.10.2025 - Börsentäglich über 12.000 News
Die 80-Milliarden-Dollar-Nuklear-Renaissance: Warum Uran der heißeste Sektor der Welt ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 856273 | ISIN: JP3942400007 | Ticker-Symbol: YPH
Tradegate
29.10.25 | 09:28
9,000 Euro
-1,06 % -0,096
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
ASTELLAS PHARMA INC Chart 1 Jahr
5-Tage-Chart
ASTELLAS PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,8228,98410:25
8,8469,02410:17

Aktuelle News zur ASTELLAS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoBayer Menopause Drug Lands FDA Approval, Bringing Competition to an Astellas Product17
SoPfizer Inc. (PFE) and Astellas Pharma Announce Survival Results from Phase 3 EMBARK Study44
DoAstellas taps social media star Babs Costello to promote Izervay for geographic atrophy5
ASTELLAS PHARMA Aktie jetzt für 0€ handeln
22.10.Astellas Pharma Announces Encouraging Data From OPTION-VMS Phase IV Study456TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY.PK), Wednesday announced new real-world preliminary data from the OPTION-VMS Phase IV study, a longitudinal, observational study in participants...
► Artikel lesen
22.10.Astellas Pharma Inc.: Astellas Presents Preliminary Real-World VEOZAH (fezolinetant) Data From OPTION-VMS Phase IV Observational Study171Extensive and growing evidence continues to reinforce fezolinetant as an effective treatment for moderate to severe VMS associated with menopause Preliminary...
► Artikel lesen
22.10.Astellas Pharma Inc.: PADCEV (enfortumab vedotin-ejfv) Plus KEYTRUDA (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer101Results from the pivotal EV-303 trial demonstrated that, when used before and after surgery, the combination reduced the risk of recurrence, progression or death...
► Artikel lesen
20.10.Astellas Reports Sustained GA Reduction With Long-Term IZERVAY Treatment In GATHER2 Extension Study511TOKYO (dpa-AFX) - Astellas Pharma Inc. announced the first results from the open-label extension (OLE) of its Phase 3 GATHER2 study, revealing that monthly treatment with IZERVAY (avacincaptad...
► Artikel lesen
18.10.Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients28
17.10.Astellas walks away from gene therapy pact with Taysha before pivotal trial launch7
17.10.I-Mab morphs into 'hub-and-spoke' biotech; Astellas passes on Taysha gene therapy7
14.10.Astellas suffers pancreatic cancer failure with Vyloy16
14.10.Astellas' Phase 2 Study GLEAM Study Of Zolbetuximab In Pancreatic Cancer Misses Primary Endpoint398 TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) on Tuesday said the Phase 2 GLEAM study of zolbetuximab in metastatic pancreatic cancer failed to meet its primary endpoint of overall survival...
► Artikel lesen
29.09.Dividendenbekanntmachungen (29.09.2025)17.521 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ACADIAN TIMBER CORP  CA0042721005  0,29 CAD  0,1777 EUR  ACOM CO LTD  JP3108600002  10 JPY  0,0572 EUR  ADVANTEST CORPORATION  JP3122400009  19...
► Artikel lesen
29.09.Astellas Announces Top Management Personnel Changes17
29.09.Astellas Pharma Inc.: Astellas Announces Top Management Personnel Change246TOKYO, Sept. 29, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the following changes to its...
► Artikel lesen
22.09.Astellas' Izervay gains conditional approval in Japan for GA treatment5
09.09.Research and Markets: Europe Liver Disease Therapeutic Market Analysis Report 2025-2033 Featuring Abbott, Astellas, BMS, Gilead Sciences, GSK, F. Hoffman-La Roche, Merck & Co., Novartis, Sanofi, Pfizer, Takeda - ResearchAndMarkets.com1.362The "Europe Liver Disease Therapeutic Market Forecast 2025" report has been added to ResearchAndMarkets.com's offering. The Europe Liver Disease Therapeutic Market is expected to grow from US$...
► Artikel lesen
05.09.Astellas attacks menopause stigma with new workplace inclusivity program6
02.09.Bernstein stuft Astellas Pharma auf "Market Perform" herab24
02.09.Bernstein downgrades Astellas Pharma stock rating to Market Perform2
Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1